Introduction: The terminology for the genitourinary tract symptoms related to menopause was vulvovaginal atrophy, which does not accurately describe the symptoms nor is a term that resonates well with patients.
Aim: In 2012, the Board of Directors of the International Society for the Study of Women's Sexual Health (ISSWSH) and the Board of Trustees of The North American Menopause Society (NAMS) acknowledged the need to review current terminology associated with genitourinary tract symptoms related to menopause.
Methods: The two societies cosponsored a terminology consensus conference, which was held in May 2013.
Main Outcome Measure: The development of a new terminology that more accurately described the genitourinary tract symptoms related to menopause.
Results: Members of the consensus conference agreed that the term genitourinary syndrome of menopause (GSM) is a medically more accurate, all-encompassing, and publicly acceptable term than vulvovaginal atrophy. GSM is defined as a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra, and bladder. The syndrome may include but is not limited to genital symptoms of dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria, and recurrent urinary tract infections. Women may present with some or all of the signs and symptoms, which must be bothersome and should not be better accounted for by another diagnosis.
Conclusion: The term GSM was presented and discussed at the annual meeting of each society. The respective Boards of NAMS and ISSWSH formally endorsed the new terminology--genitourinary syndrome of menopause--in 2014.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jsm.12686 | DOI Listing |
Menopause
January 2025
Cosette Pharmaceuticals, Inc, Bridgewater, NJ.
Objective: The aims of this study were to assess the prevalence of urinary tract infections (UTI) in women newly diagnosed with vulvovaginal atrophy (VVA) versus women without VVA and to evaluate the potential of vaginal prasterone to be used in postmenopausal VVA women with UTI as prophylaxis to reduce the future UTI risk. As a first subgroup analysis, women using aromatase inhibitors, medications that stop the production of estrogen were analyzed. As a second subgroup analysis, we looked at women with diabetes to investigate whether the same prophylaxis approach should be considered.
View Article and Find Full Text PDFExpert Opin Pharmacother
January 2025
Femicare vzw, Tienen, Belgium.
Introduction: Vulvovaginal atrophy (VVA) predominantly affects postmenopausal women due to hormonal decline but can also occur in premenopausal women with conditions such as primary ovarian insufficiency or exposure to anti-estrogen medications. Contributing factors include smoking and certain medical treatments. Symptoms like dyspareunia and loss of sexual function affect many women but are underreported due to stigma and lack of awareness.
View Article and Find Full Text PDFBreast Cancer Res Treat
December 2024
Comprehensive Cancer Center, Helsinki University Hospital, University of Helsinki, PO Box 180, 00290, Helsinki, Finland.
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA). Secondary objectives included assessing the effects of therapy on vaginal atrophy, quality of life (QoL) and menopause-related symptoms.
Methods: 20 postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks.
Int J Gynaecol Obstet
December 2024
Department of Menopause, Instituto Nacional de Perinatología, Mexico City, Mexico.
Int Urogynecol J
December 2024
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Introduction And Hypothesis: Women with genitourinary syndrome of menopause (GSM) may have anxiety and depression; however, this is unclear.
Methods: A total of 646 postmenopausal women undergoing treatment for menopausal symptoms were enrolled in this retrospective cross-sectional study. Questionnaire responses were recorded at the first visit, and participants were divided into GSM (≥1 moderate or severe GSM symptom) or no-GSM (without any moderate/severe symptoms) groups.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!